Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geoffrey R Oxnard

Showing results (181-190 of 199) with videos related to

Pageof 20
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 9, 2021
Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance MechanismsHanna Tukachinsky, Russell W Madison, Jon H Chung, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2018
Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA SequencingThomas P Slavin, Kimberly C Banks, Darya Chudova, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 9, 2020
Use of <i>Ex</i> <i>Vivo</i> Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for <i>HER2</i> Mutant Non-Small Cell Lung CancerElena Ivanova, Mari Kuraguchi, Man Xu, et al.
Cancer Discovery|September 15, 2022
Serial Profiling of Circulating Tumor DNA Identifies Dynamic Evolution of Clinically Actionable Genomic Alterations in High-Risk NeuroblastomaKristopher R Bosse, Anna Maria Giudice, Maria V Lane, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 9, 2020
Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLCGonzalo Recondo, Magda Bahcall, Liam F Spurr, et al.
Nature Communications|September 24, 2022
Genomic and biological study of fusion genes as resistance mechanisms to EGFR inhibitorsYoshihisa Kobayashi, Geoffrey R Oxnard, Elizabeth F Cohen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 14, 2023
Germline <i>EGFR</i> Mutations and Familial Lung CancerGeoffrey R Oxnard, Ruthia Chen, Jennifer C Pharr, et al.
Science Translational Medicine|December 20, 2013
Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancerHiroyuki Yasuda, Eunyoung Park, Cai-Hong Yun, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 22, 2025
ctDNA Clearance as an Early Indicator of Improved Clinical Outcomes in Advanced NSCLC Treated with TKI: Findings from an Aggregate Analysis of Eight Clinical TrialsHillary S Andrews, Nevine Zariffa, Katherine K Nishimura, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 30, 2025
Efficacy and Safety of Olomorasib in Combination With Pembrolizumab in Treatment of Patients With KRAS G12C-Mutant Advanced NSCLCTimothy F Burns, Natraj Reddy Ammakkanavar, Antoine Hollebecque, et al.
Pageof 20

Showing results (181-190 of 199) with videos related to

Sort By:
Pageof 20
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 9, 2021
Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance MechanismsHanna Tukachinsky, Russell W Madison, Jon H Chung, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2018
Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA SequencingThomas P Slavin, Kimberly C Banks, Darya Chudova, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 9, 2020
Use of <i>Ex</i> <i>Vivo</i> Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for <i>HER2</i> Mutant Non-Small Cell Lung CancerElena Ivanova, Mari Kuraguchi, Man Xu, et al.
Cancer Discovery|September 15, 2022
Serial Profiling of Circulating Tumor DNA Identifies Dynamic Evolution of Clinically Actionable Genomic Alterations in High-Risk NeuroblastomaKristopher R Bosse, Anna Maria Giudice, Maria V Lane, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 9, 2020
Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLCGonzalo Recondo, Magda Bahcall, Liam F Spurr, et al.
Nature Communications|September 24, 2022
Genomic and biological study of fusion genes as resistance mechanisms to EGFR inhibitorsYoshihisa Kobayashi, Geoffrey R Oxnard, Elizabeth F Cohen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 14, 2023
Germline <i>EGFR</i> Mutations and Familial Lung CancerGeoffrey R Oxnard, Ruthia Chen, Jennifer C Pharr, et al.
Science Translational Medicine|December 20, 2013
Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancerHiroyuki Yasuda, Eunyoung Park, Cai-Hong Yun, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 22, 2025
ctDNA Clearance as an Early Indicator of Improved Clinical Outcomes in Advanced NSCLC Treated with TKI: Findings from an Aggregate Analysis of Eight Clinical TrialsHillary S Andrews, Nevine Zariffa, Katherine K Nishimura, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 30, 2025
Efficacy and Safety of Olomorasib in Combination With Pembrolizumab in Treatment of Patients With KRAS G12C-Mutant Advanced NSCLCTimothy F Burns, Natraj Reddy Ammakkanavar, Antoine Hollebecque, et al.
Pageof 20